How chromatin domains are established and maintained in higher eukaryotes are poorly understood, especially during development. Covalent modifications of histones carry significant amount of information that complement to genetic information in dictating developmental process. Mutations in histone modifying enzymes are commonly found in human diseases, further underlying their fundamental roles in cells. One such enzyme is MLL1 (mixed lineage leukemia), which is evolutionarily conserved and promotes 5'Hox gene transcription. MLL1 is a histone methyltransferase for H3 lysine 4, a mark highly enriched at gene promoters and enhancers. Studies have found that MLL1 plays important roles in normal and malignant hematopoiesis. Knockout MLL1 gene leads to profound defects in hematopoietic stem cells compartment and blocks MLL1 fusion protein mediated leukemogenesis. Despite these findings, the obligatory function of H3 K4 methylation in MLL1 dependent biological pathways remains unclear. Our biochemical studies have revealed that the MLL1 methyltransferase activity is tightly regulated by three proteins including WDR5, RbBP5 and ASH2L. We, and others, further demonstrate that MLL1-WDR5 interaction is essential for complex integrity. Blocking this interaction abolishes MLL1 activity. Based on these results, we have developed a highly specific chemical probe that targets MLL1 methyltransferase activity by disrupting MLL1 complex assembly. Using this novel probe, we will directly address the function of MLL1 mediated H3 K4 methylation in malignant process (without affecting other MLL1 functions). This novel probe also, for the first time, allows us to examine the dynamic and reversible functions of H3K4 methylation during normal cell differentiation. Our studies will have high impact in the chromatin field and translational research.
Mixed lineage leukemia (MLL) is a form of cancer in which the normal development of blood cells is blocked and the cells abnormally proliferate. Mutations in MLL gene associate with ~10% AML and ALL cases in both children and adults. The goal of work is to understand the fundamental mechanism of MLL1-mediated transcription regulation and other cellular processes. Our studies will lay foundations for developing further therapeutics.
|Sun, Yuqing; Zhou, Bo; Mao, Fengbiao et al. (2018) HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. Cancer Cell 34:643-658.e5|
|Gupta, Ankit; Xu, Jing; Lee, Shirley et al. (2018) Facile target validation in an animal model with intracellularly expressed monobodies. Nat Chem Biol 14:895-900|
|Khoa, Le Tran Phuc; Dou, Yali (2017) Phosphoproteomics links glycogen synthase kinase-3 to RNA splicing. J Biol Chem 292:18256-18257|
|Zhang, Hui; Dou, Yali (2017) Reprogram Murine Epiblast Stem Cells by Epigenetic Inhibitors. Bio Protoc 7:|
|Albert, Lea; Xu, Jing; Wan, Ruiwei et al. (2017) Controlled inhibition of methyltransferases using photoswitchable peptidomimetics: towards an epigenetic regulation of leukemia. Chem Sci 8:4612-4618|
|Wang, Weimin; Kryczek, Ilona; Dostál, Lubomír et al. (2016) Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell 165:1092-1105|
|Li, Yanjing; Han, Jianming; Zhang, Yuebin et al. (2016) Structural basis for activity regulation of MLL family methyltransferases. Nature 530:447-52|
|Xu, Jing; Li, Li; Xiong, Jie et al. (2016) MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program. Cell Discov 2:16008|
|Zhou, Bo; Wang, Jingya; Lee, Shirley Y et al. (2016) PRDM16 Suppresses MLL1r Leukemia via Intrinsic Histone Methyltransferase Activity. Mol Cell :|
|Nagarsheth, Nisha; Peng, Dongjun; Kryczek, Ilona et al. (2016) PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Res 76:275-82|
Showing the most recent 10 out of 29 publications